
Precision BioSciences DTIL
$ 4.31
2.62%
Quarterly report 2025-Q3
added 11-03-2025
Precision BioSciences Interest Expense 2011-2026 | DTIL
Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.Includes:
- Interest on bank loans
- Interest on corporate bonds
- Interest on leases
- Interest on credit lines and overdrafts
High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.
Low interest expenses with high profits are a sign of financial stability.
Annual Interest Expense Precision BioSciences
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.23 M | 1.11 M | 132 K | 822 K | 182 K | 1.88 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.23 M | 132 K | 1.06 M |
Quarterly Interest Expense Precision BioSciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.1 M | -1.64 M | 354 K | - | 4.85 M | 8.6 M | 574 K | - | 576 K | 553 K | 522 K | - | 405 K | 178 K | 42 K | - | 55 K | 24 K | 53 K | - | 28 K | 107 K | 660 K | - | 182 K | 182 K | 182 K | - | 691 K | 299 K | 223 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 8.6 M | -1.64 M | 691 K |
Interest Expense of other stocks in the Biotechnology industry
| Issuer | Interest Expense | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
4.66 M | - | 2.43 % | $ 254 M | ||
|
Xeris Pharmaceuticals
XERS
|
-24.3 M | $ 6.03 | -1.55 % | $ 885 M | ||
|
I-Mab
IMAB
|
722 K | - | - | $ 866 M | ||
|
UroGen Pharma Ltd.
URGN
|
-284 K | $ 19.2 | -11.52 % | $ 554 M | ||
|
uniQure N.V.
QURE
|
10.9 M | $ 10.89 | -30.36 % | $ 530 M | ||
|
GT Biopharma
GTBP
|
156 K | $ 0.47 | -2.41 % | $ 892 K | ||
|
AbCellera Biologics
ABCL
|
-2.71 M | $ 3.74 | 3.6 % | $ 1.12 B | ||
|
Adverum Biotechnologies
ADVM
|
8.23 M | - | - | $ 86.2 M | ||
|
ARCA biopharma
ABIO
|
9 K | - | 1052.0 % | $ 415 M | ||
|
Acer Therapeutics
ACER
|
432 K | - | 2.71 % | $ 14 M | ||
|
Alpine Immune Sciences
ALPN
|
476 K | - | - | $ 2.17 B | ||
|
Acorda Therapeutics
ACOR
|
31.5 M | - | -24.86 % | $ 820 K | ||
|
AgeX Therapeutics
AGE
|
4.9 M | - | -10.17 % | $ 12.2 K | ||
|
Aeglea BioTherapeutics
AGLE
|
29.5 M | - | - | $ 1.01 B | ||
|
Applied Genetic Technologies Corporation
AGTC
|
2.67 M | - | - | $ 26.5 M | ||
|
AIkido Pharma
AIKI
|
-5.79 M | - | 1.93 % | $ 17.4 M | ||
|
Agenus
AGEN
|
1.26 M | $ 3.36 | 0.86 % | $ 1.2 M | ||
|
Akero Therapeutics
AKRO
|
4.67 M | - | - | $ 3.67 B | ||
|
Agios Pharmaceuticals
AGIO
|
1.96 M | $ 29.16 | -3.54 % | $ 1.69 B | ||
|
Advaxis
ADXS
|
28 K | - | -9.65 % | $ 45.9 M | ||
|
Akouos
AKUS
|
-1.72 M | - | 0.23 % | $ 488 M | ||
|
Albireo Pharma
ALBO
|
3.69 M | - | -0.23 % | $ 916 M | ||
|
Alector
ALEC
|
13.2 M | $ 2.19 | -9.77 % | $ 226 M | ||
|
Allena Pharmaceuticals
ALNA
|
-38 K | - | 3.16 % | $ 1.9 M | ||
|
Aileron Therapeutics
ALRN
|
685 K | - | 10.36 % | $ 9.8 M | ||
|
Altimmune
ALT
|
48 K | $ 4.21 | -2.32 % | $ 299 M | ||
|
AlloVir
ALVR
|
1.19 M | - | 4.14 % | $ 49.1 M | ||
|
Ampio Pharmaceuticals
AMPE
|
-5.01 K | - | -11.43 % | $ 502 K | ||
|
Amarin Corporation plc
AMRN
|
7 K | $ 13.98 | 1.27 % | $ 5.7 B | ||
|
AbbVie
ABBV
|
2.89 B | $ 233.57 | 0.64 % | $ 413 B | ||
|
Blueprint Medicines Corporation
BPMC
|
656 K | - | - | $ 8.14 B | ||
|
Applied Molecular Transport
AMTI
|
-4 K | - | - | $ 10.1 M | ||
|
AIM ImmunoTech
AIM
|
629 K | $ 0.8 | -11.6 % | $ 38.5 M | ||
|
Apellis Pharmaceuticals
APLS
|
-133 K | $ 20.67 | -1.38 % | $ 2.61 B |